Catalyst Pharmaceuticals Inc (CPRX)

1.07
0.01 0.94
NASDAQ : Health Care
Prev Close 1.06
Open 1.10
Day Low/High 1.04 / 1.10
52 Wk Low/High 0.51 / 4.52
Volume 842.19K
Avg Volume 981.10K
Exchange NASDAQ
Shares Outstanding 82.87M
Market Cap 84.53M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Catalyst Pharmaceuticals Announces Agreement With FDA On Confirmatory Phase 3 Study Protocol For Firdapse In Lambert-Eaton Myasthenic Syndrome

Catalyst Pharmaceuticals Announces Agreement With FDA On Confirmatory Phase 3 Study Protocol For Firdapse In Lambert-Eaton Myasthenic Syndrome

Reorganized operations plan projects that current capital resources are adequate to reach NDA acceptance

Catalyst Pharmaceuticals Announces First Quarter 2016 Financial Results And Provides Corporate Update

Catalyst Pharmaceuticals Announces First Quarter 2016 Financial Results And Provides Corporate Update

Company to Host Quarterly Conference Call at 8:30 am EDT Tomorrow

Anavex Plays the Orphan Drug Stock Promotion Game

Anavex Plays the Orphan Drug Stock Promotion Game

Too many investors have a fundamental misunderstanding about the significance of orphan drug designation. I should say, insignificance, because the FDA delineation, on its own, means very little.

Catalyst Pharmaceuticals Announces Fourth Quarter And Year-End 2015 Financial Results

Catalyst Pharmaceuticals Announces Fourth Quarter And Year-End 2015 Financial Results

Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow

Catalyst Pharmaceuticals (CPRX) Stock Plunges After FDA 'Refusal to File' Letter

Catalyst Pharmaceuticals (CPRX) Stock Plunges After FDA 'Refusal to File' Letter

Catalyst Pharmaceuticals (CPRX) stock is sinking on heavy trading volume on Wednesday after the company announced that it received a 'Refusal to File' letter from the FDA.

Catalyst Pharma Plummets on FDA 'Refuse-to-File' Letter

Catalyst Pharma Plummets on FDA 'Refuse-to-File' Letter

The FDA deems the approval application for the Catalyst drug Firdapse to be 'not sufficiently complete' and requests additional information.

Interesting CPRX Call Options For September 16th

Interesting CPRX Call Options For September 16th

Investors in Catalyst Pharmaceuticals Inc saw new options begin trading this week, for the September 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Catalyst Pharmaceuticals Announces Third Quarter 2015 Financial Results And Provides Corporate Update

Catalyst Pharmaceuticals Announces Third Quarter 2015 Financial Results And Provides Corporate Update

Company to host quarterly conference call at 8:30am ET tomorrow